Form 4: Sage Therapeutics Executive Gregory Shiferman Reports Stock Transaction
SEC Form 4
Gregory Shiferman, a Senior Vice President at Sage Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations upon the vesting of restricted stock units.
Summary
- On December 24, 2024, Gregory Shiferman, Senior Vice President, General Counsel and Secretary of Sage Therapeutics, had 79 shares of common stock withheld to cover tax obligations.
- This transaction occurred due to the vesting of 235 time-based restricted stock units (RSUs) granted on October 28, 2021, under the company's 2014 Stock Option and Incentive Plan.
- The RSUs vested 25% on September 24, 2022, and then quarterly in twelve equal installments.
- Following the transaction, Shiferman directly owns 19,888 shares of Sage Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a neutral report on a routine stock transaction related to executive compensation.
Industry Context
This is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a standard procedure for covering tax obligations.
Key Dates
| Date | Description |
|---|---|
| October 28, 2021 | Date of grant for time-based restricted stock units (RSUs). |
| September 24, 2022 | Initial vesting date (25%) of the RSUs. |
| December 24, 2024 | Date of the reported transaction where shares were withheld for tax obligations. |
| December 27, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.